Abstract | BACKGROUND: PATIENTS AND METHODS: In this trial involving double randomization, 140 patients were randomized to receive modified FOLFOX7 plus bevacizumab with IO (eight-cycle blocks of oxaliplatin treatment) versus continuous oxaliplatin (CO); and Ca/Mg versus placebo (pre- and postoxaliplatin infusion). The primary end point was time-to-treatment failure (TTF). RESULTS: One hundred thirty-nine patients were entered and treated up to the point of early study termination due to concerns by the data-monitoring committee (DMC) that Ca/Mg adversely affected tumor response. Tumor response was not a study end point. Given DMC concerns, an additional independent, blinded radiology review of all images showed no adverse effect of treatment schedule or Ca/Mg on response by Response Evaluation Criteria In Solid Tumors. The IO schedule was superior to CO [hazard ratio (HR) = 0.581, P = 0.0026] for both TTF and time-to- tumor progression ( TTP) (HR = 0.533, P = 0.047). CONCLUSIONS: An IO dosing schedule had a significant benefit on both TTF and TTP versus CO dosing in this trial despite the very attenuated sample. There was no effect of Ca/Mg on response.
|
Authors | H S Hochster, A Grothey, L Hart, K Rowland, R Ansari, S Alberts, N Chowhan, R K Ramanathan, M Keaton, J D Hainsworth, B H Childs |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 25
Issue 6
Pg. 1172-8
(Jun 2014)
ISSN: 1569-8041 [Electronic] England |
PMID | 24608198
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected]. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Organoplatinum Compounds
- Oxaliplatin
- Bevacizumab
- Magnesium Sulfate
- Leucovorin
- Calcium Gluconate
- Fluorouracil
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Bevacizumab
- Calcium Gluconate
(administration & dosage)
- Colorectal Neoplasms
(drug therapy, mortality)
- Double-Blind Method
- Female
- Fluorouracil
- Humans
- Kaplan-Meier Estimate
- Leucovorin
- Magnesium Sulfate
(administration & dosage)
- Male
- Middle Aged
- Organoplatinum Compounds
(administration & dosage, adverse effects)
- Oxaliplatin
- Proportional Hazards Models
|